Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03087708 · ClinicalTrials.gov registry record · Phase 2
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT03087708 is a Phase 2 study that was terminated before completion, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 50 participants.
The verdict
NCT03087708, a Phase 2 study, was terminated before completion, sponsored by Alliance for Clinical Trials in Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer. Naloxegol may relieve some of the side effects of opioid pain medication and fight off future growth in the cancer.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DRUG Naloxegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-03-23 |
| Est. Completion | 2023-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03087708
The ClinicalTrials.gov registry entry for NCT03087708 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03087708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03087708 about?
NCT03087708 is a clinical study titled "Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer". This randomized pilot clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer. Naloxegol may relieve some of the side effects of opioid pain medication and fight off future growth in the cancer...
What is the current status of trial NCT03087708?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2018-03-23. Estimated completion is 2023-04-01.
What interventions are being tested in trial NCT03087708?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Naloxegol (DRUG).
Who is sponsoring clinical trial NCT03087708?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.